2014 News Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/18/14StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
Pathway Study to Assess the Potential of Human Neural Stem Cells to Restore Motor Function NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform techn... 
Printer Friendly Version
12/02/14StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
NEWARK, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leader in the development of cell-based therapies for disorders of the central nervous system (CNS), hosted its first investor and analyst event in New York, on November 20, 2014. The event was well-attended by biotech investing VIPs including representatives from Maxim Group, Piper Jaffray, Brinson Patrick Securities, Needham and Company, H.C. Wainwright and Company, Cantor Fitzgerald, Ladenburg Thalmann and M... 
Printer Friendly Version
11/20/14StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, will host its first investor and analyst event today, November 20, 2014, in New York. The program will feature a keynote address from Irving L. Weissman M... 
Printer Friendly Version
11/05/14StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results
StemCells, Inc. to Host Investor and Analyst Event in New York, November 20, 2014 NEWARK, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), which pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today reported financial results for the third quarter ended September 30,... 
Printer Friendly Version
11/03/14StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
NEWARK, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today announced that it will host its first investor and analyst event in New York, November 20, 2014. "Our Company has begun the transformation from small... 
Printer Friendly Version
10/07/14StemCells, Inc. Initiates Phase II Clinical Trial in Cervical Spinal Cord Injury
First Study Assessing Efficacy of Neural Stem Cells for the Treatment of Cervical Spinal Cord Injury NEWARK, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell based therapies for the treatment of disorders of the central nervous system, announced today that it has initiated its Pathway® Study, a Phase II proof of concept clinical trial using its proprietary HuCNS-SC® platform of human neural stem cells for the treatmen... 
Printer Friendly Version
10/01/14StemCells, Inc. to Participate at the 2014 Stem Cell Meeting on the Mesa
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 4th Annual Partnering Forum, part of the 2014 Stem Cell Meeting on the Mesa, to be held October 7-9. Mr. McGlynn is scheduled to speak at 3:15 p.m. Pacific Time on Tuesday, October 7, at the Estancia La Jolla... 
Printer Friendly Version
09/04/14StemCells, Inc. to Participate at the 16th Annual Rodman & Renshaw Global Investment Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Sept. 4, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 16th Annual Rodman & Renshaw Global Investment Conference Wednesday, September 10, at 9:10 AM EDT in the Holmes II Salon room at the New York Palace Hotel, 455 Madison Avenue, New York, NY. Management is scheduled to present an update on the Company's programs, pipeline and ope... 
Printer Friendly Version
08/12/14StemCells, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
Conference Call to Be Hosted August 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the second quarter ended June 30, 2014. "The highlight for the quarter was the release of the first interim data from our ongoing... 
Printer Friendly Version
08/05/14StemCells, Inc. Announces Webcast to Discuss Second Quarter 2014 Financial Results
NEWARK, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the second quarter ended June 30, 2014 after the market close on Tuesday, August 12. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacif... 
Printer Friendly Version
07/18/14StemCells, Inc. Announces Closing of $20 Million Offering
NEWARK, Calif., July 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced that it has closed its previously announced offering of common stock and short term warrants. The Company sold a total of 11,299,435 units to two well recognized institutional biotechnology investors and received total proceeds, net of offering expenses and placement agent fees, of approximately $18.7 million. Each unit consists of one share of common stock and a warrant to purchase 0.85 of a share o... 
Printer Friendly Version
07/15/14StemCells, Inc. Announces Proposed $20 Million Offering
NEWARK, Calif., July 15, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), today announced its intent to offer and sell 11,299,435 shares of common stock and short term warrants for the purchase of up to 9,604,520 additional shares of common stock to two well recognized institutional biotechnology investors, subject to market and other conditions, for gross proceeds of $20 million, before deducting placement fees and other offering expenses. StemCells intends to use the net proceeds of the... 
Printer Friendly Version
07/07/14StemCells, Inc. Appoints Dr. Alan Trounson to Board of Directors
NEWARK, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today the appointment of Alan Trounson, Ph.D. to its Board of Directors. Dr. Trounson most recently served as President of The California Institute of Regenerative Medicine (CIRM), the largest scientific funding body for stem cell research in the world. "We are thrilled to welcome Dr. Trounson to our Board," said Martin McGlynn, president and CEO of StemCells, Inc. "His diverse background includes ground... 
Printer Friendly Version
06/23/14StemCells, Inc. President and CEO Martin McGlynn to Present on a Regenerative Medicine Panel at the 2014 BIO International Convention
NEWARK, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will be a panelist at the 2014 BIO International Convention on June 25, 2014 at 4:15 pm PDT. Mr. McGlynn will participate in the panel discussion, "How International Collaboration is Accelerating the Field." This panel will showcase examples of international collaboration that are producing results or initiating new approaches to cross-border research. Under Mr. M... 
Printer Friendly Version
06/20/14StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry Age-Related Macular Degeneration Trial
Phase II Clinical Trial to Begin This Year NEWARK, Calif., June 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) yesterday announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the current AMD trial show a 70 percent reduction in the rate of geograph... 
Printer Friendly Version
06/19/14StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial
Company to Host Webcast to Discuss Interim Data Today NEWARK, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada. Interim trial results show a 65 percent redu... 
Printer Friendly Version
06/17/14StemCells, Inc. Strengthens Senior Executive Team
NEWARK, Calif., June 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today one promotion and three new appointments to the Company's executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells, Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has join... 
Printer Friendly Version
05/29/14StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., May 29, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. Dear Fellow Shareholders, As I mentioned in my last letter to shareholders, the pace of development at StemCells, Inc. has been accelerating quickly, so it is especially important to have regular updates ... 
Printer Friendly Version
05/29/14StemCells, Inc. to Participate at the 4th LD Micro Invitational Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., May 29, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 4th LD Micro Invitational Conference, on Wednesday, June 4, at 11:30 AM PDT at the Luxe Hotel, 11461 Sunset Boulevard, in Los Angeles. Management is scheduled to present an update on the Company's programs, pipeline and operations. A live webcast of the presentation will be avai... 
Printer Friendly Version
05/22/14StemCells, Inc. Advances Clinical Trial in Age-Related Macular Degeneration to Final Cohort
Phase I/II AMD Trial on Track to Complete Enrollment in June NEWARK, Calif., May 22, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has transplanted the Company's proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD). Each of the eight patients in this second cohort will receive a dose of 1 million stem cel... 
Printer Friendly Version
05/19/14StemCells, Inc. Provides Update on Its Phase I/II Study in Spinal Cord Injury
Significant Sensory Gains Observed in Additional Patients NEWARK, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in... 
Printer Friendly Version
05/14/14StemCells, Inc. Reports First Quarter 2014 Financial Results and Provides Business Update
Conference Call to be Hosted May 14, 2014 at 4:30 p.m. EDT NEWARK, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the first quarter ended March 31, 2014. "We have made substantial progress in our clinical programs this past quarter," said Martin M... 
Printer Friendly Version
05/01/14StemCells, Inc. Announces Webcast to Discuss First Quarter 2014 Financial Results
NEWARK, Calif., May 1, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter ended March 31, 2014 after the market close on Wednesday, May 14. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific... 
Printer Friendly Version
04/17/14StemCells, Inc. Completes Enrollment in Spinal Cord Injury Trial
Interim Data to be Presented at Upcoming American Spinal Injury Association Conference NEWARK, Calif., April 17, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company's Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.'s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. Th... 
Printer Friendly Version
03/19/14StemCells, Inc. to Participate at the 13th Annual Needham Healthcare Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will present at the 13th Annual Needham Healthcare Conference, on Wednesday, April 9, at 8:40 AM EDT at the Westin Grand Central Hotel, 212 East 42nd Street, in New York City. Management is scheduled to present an update on the Company's programs, pipeline and operations. A live webcast of the pr... 
Printer Friendly Version
03/12/14StemCells, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results and Provides Business Update
Conference Call to be Hosted March 12, 2014 at 4:30 p.m. EDT NEWARK, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2013. "2013 was a year of significant clinical and regulatory progress for StemCel... 
Printer Friendly Version
03/10/14StemCells, Inc. to Participate at 2014 Regen Med Investor Day in New York
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the 2nd Annual Regen Med Investor Day, Wednesday, March 26, 2014, at 3:30 pm EDT at the Metropolitan Club, One East 60th Street, in New York City. Mr. McGlynn is scheduled to present an update on the Company's programs, pipeline and operations. Organized ... 
Printer Friendly Version
03/05/14StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results
NEWARK, Calif., March 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2013 after the market close on Wednesday, March 12. StemCells will host a conference call and webcast to discuss its results and an update on its busines... 
Printer Friendly Version
02/12/14StemCells, Inc. Announces Completion of the First of Two Cohorts in its Dry Age-Related Macular Degeneration Trial
NEWARK, Calif., Feb. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment of the first of two planned patient cohorts in the Company's clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for dry age-related macular degeneration (AMD). This cohort consisted of eight subjects, four of whom each received 200,000 cells and four of whom each received 1,000,000 cells. The last patient in this cohort was... 
Printer Friendly Version
01/30/14StemCells, Inc. Announces Presentation at Two Upcoming Investor Conferences
President and CEO Martin McGlynn Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the following conferences: 16th Annual BIO CEO & Investor Conference in New York on February 10, 2014, at 2:30 p.m. EST Leerink Swann 2014 Global Healthcare Conference in New York on February 12, 2014 at 3:00 p.m. EST As Martin McGlynn,... 
Printer Friendly Version
01/13/14StemCells, Inc. Technology is Featured in Canadian TV Broadcast
In an Extended Segment Dr. Michael Fehlings Discusses the Importance of This Technology in Spinal Cord Injury NEWARK, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that its technology was featured January 10 in a television segment which aired at 10 PM on CTV News Channel and 11 PM on the CTV National News. The story, titled 'Start of stem-cell study offers hope to patients with spinal cord injuries,' includes an interview with the first subject being t... 
Printer Friendly Version
01/10/14StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America
First Subject in Canada Transplanted at the University of Calgary NEWARK, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC® human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury pa... 
Printer Friendly Version
01/07/14StemCells, Inc. to Discuss Plans for Advancing Clinical Studies in Spinal Cord Injury and Age Related Macular Regeneration
Company to Present at 2014 Alliance for Regenerative Medicine State of the Industry Briefing NEWARK, Calif., Jan. 7, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Eliseo Salinas, M.D., Executive Vice President and Head of Research and Development, will provide an update on the StemCells, Inc. development programs and translational work being done with the Company's proprietary HuCNS-SC® human neural stem cells, at the 2014 Alliance for Regenerative Medicine (ARM) S... 
Printer Friendly Version
01/06/14StemCells, Inc. Posts Letter to Shareholders
NEWARK, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn. Dear Fellow Shareholders, Every day, the news media brings us word of some new advancement in the development of stem cell therapies. While you clearly comprehend the vast potential of stem cell therapeut... 
Printer Friendly Version